Monteris AutoLITTâ„¢ FIM Safety Trial for Recurrent/Progressive Brain Tumors
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
Brain Tumor|Brain Tumor, Recurrent|Brain Neoplasm|Brain Cancer|Glioblastoma Multiforme|Recurrent Glioblastoma Multiforme
DEVICE: AutoLITT system
Primary endpoint is safety, as determined by absence of severe clinical toxicity or procedure-related neurological deficits, 14 days post-surgery
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).